View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 25, 2021updated 12 Jul 2022 11:21am

BMS’ relatlimab plus Opdivo meets primary endpoint in melanoma trial

Bristol Myers Squibb (BMS) has reported primary results from the Phase II/III RELATIVITY-047 (CA224-047) trial of a fixed-dose combination of relatlimab and Opdivo (nivolumab) in patients with previously untreated metastatic or unresectable melanoma. 

Bristol Myers Squibb (BMS) has reported primary results from the Phase II/III RELATIVITY-047 (CA224-047) trial of a fixed-dose combination of relatlimab and Opdivo (nivolumab) in patients with previously untreated metastatic or unresectable melanoma.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

An anti-LAG-3 antibody, relatlimab attaches to LAG-3 on T cells, restoring the effector function of exhausted T cells.

The randomised, double-blind Phase II/III study evaluated the fixed-dose combination of relatlimab and Opdivo in patients with previously untreated metastatic or unresectable melanoma as compared with Opdivo alone.

It enrolled a total of 714 trial participants who randomly received a fixed-dose combination of relatlimab 160mg plus Opdivo 480mg or Opdivo 480mg by intravenous infusion every four weeks until disease recurrence, unacceptable toxicity or withdrawal of consent.

Progression-free survival (PFS) formed the trial’s primary endpoint while secondary endpoints concluded overall survival (OS) and objective response rate (ORR).

Data showed that the trial met its primary endpoint of PFS while following up for OS is progressing.

The treatment with relatlimab plus Opdivo was well-tolerated with no new safety signals observed in either the combination arm or the Opdivo arm.

These are the first Phase III data to be reported from a trial evaluating an anti-LAG-3 antibody.

BMS noted that relatlimab is the third distinct checkpoint inhibitor (anti-PD-1, anti-CTLA-4 and anti-LAG-3) for the company and, with Opdivo, the first fixed-dose combination to show benefit in patients.

Bristol Myers Squibb senior vice-president and oncology development head Jonathan Cheng said: “Immune checkpoint inhibitors alone or in combination have transformed treatment and improved survival rates for patients with metastatic or unresectable melanoma.

“However, there remain a considerable number of patients who could benefit from a novel combination therapy that leverages potentially complementary pathways to improve anti-tumour activity.

“The results of this study suggest that targeting the LAG-3 pathway in combination with PD-1 inhibition may be a key strategy to enhance the immune response and help improve outcomes for these patients.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena